Rainmed Medical (HKSE:02297) ROCE % : -16.26% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Rainmed Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rainmed Medical's annualized ROCE % for the quarter that ended in Jun. 2024 was -16.26%.

Rainmed Medical ROCE % Historical Data

The historical data trend for Rainmed Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rainmed Medical ROCE % Chart

Rainmed Medical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-858.61

-207.09

-211.72

-19.83

Rainmed Medical Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-407.13	-42.25	-15.38	-23.84	-16.26

Rainmed Medical ROCE % Calculation

Rainmed Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-126.637	/	( ( (770.902 - 76.069)	+	(627.072 - 44.825) )	/ 2 )
	=	-126.637	/	( (694.833	+	582.247)	/ 2 )
	=	-126.637	/	638.54
	=	-19.83 %

Rainmed Medical's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-90.406	/	( ( (627.072 - 44.825)	+	(646.781 - 116.851) )	/ 2 )
	=	-90.406	/	( ( 582.247	+	529.93 )	/ 2 )
	=	-90.406	/	556.0885
	=	-16.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Rainmed Medical (HKSE:02297) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rainmed Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Rainmed Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rainmed Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rainmed Medical Ltd (HKSE:02297) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 99, Jinji Lake Avenue, Building 31, Northeast District, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.rainmed.com

Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.

Executives

Huo Yunfei	2101 Beneficial owner
Zhou Bin
Zhong Guo Ping An Bao Xian Ji Tuan Gu Fen You Xian Gong Si
Xi Zang Jing Jia Qi Ye Guan Li You Xian Ze Ren Gong Si
Shang Hai Jing Lin Gu Quan Tou Zi Guan Li You Xian Gong Si
Shang Hai Jing Wu Tou Zi Zhong Xin You Xian He Huo
Shang Hai Jing Mai Run Qi Ye Guan Li Zhong Xin You Xian He Huo
Gong Qing Cheng Jing Cheng Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Gong Qing Cheng Jing Lin Jing Jia Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Jing Lin Zi Ben Guan Li You Xian Gong Si
Shen Zhen Jing Lin Jing Ying Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Shen Zhen Jing Hui Gu Quan Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Shang Hai Tong Xiang Hao Qian Qi Ye Guan Li He Huo Qi Ye You Xian He Huo
Xi Zang Jing Ning Qi Ye Guan Li You Xian Ze Ren Gong Si
Liu Li Rui

Rainmed Medical Headlines

No Headlines